Adial Pharma earnings
ADIL Stock ,Adial Pharma reported on Monday third quarter results which beat analyst estimates and revenues that were in line with expectations.
Adial Pharma announced earnings per share of $-0.120 on revenues of $0.00. According to analysts polled Investing expected earnings per share of $-0.180 with a revenue of $0.00.
Adial Pharma shares are down 67% from the beginning of the year and are trading at $0.272 , down-from-52-week-high.
Adial Pharma shares lost 0.44 percent in trading during the day, according to the report.
Adial Pharma follows other major Health sector earnings this month
The report of Adial Pharma is the result of an earnings beat reported by J&J on Tuesday 18 October 2022. J&J reported EPS in the range of $2.55 with a revenue of $23.79B in comparison to the forecast earnings of $2.48 on revenues of $23.36B.
Eli Lilly had beat expectations on November 1 2022, with the third quarter earnings of $1.98 on revenues of $6.94B which was higher than the expectations of $1.91 on revenues of $6.91B.
Adial Pharmaceuticals Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| ADIL | -83.83% | -90% | ||
| S&P | -8.93% | +57.20% | +9.47% | +46% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $5.75M | -19.9% |
| Accounts Receivable | – | – |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $0.17M | -25.0% |
| Short Term Debt | $0.05M | +14.9% |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -172.6% | -5.8% |
| Return On Invested Capital | -212.8% | +686.8% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$3.39M | -3.8% |
| Operating Free Cash Flow | -$3.39M | -3.8% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 7.67 | 12 | 2.97 | 1.14 | -93.0% |
| Price to Sales | – | – | – | – | – |
| Price to Tangible Book Value | 7.82 | 12.94 | 3.04 | 1.17 | -93.0% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -11.24 | -11.20 | -6.20 | -1.09 | -94.3% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -518.4% | -214.4% | -264.3% | -249.0% | +4.2% |
| Total Debt | $0.26M | $0.25M | $0.23M | $0.22M | -17.8% |
